Verdad Advisers’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
Other funds holding ZNTL
SFCM
Verdad Advisers's ZNTL Position: Q3 2026 in Review
Verdad Advisers sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2026, closing a stake of 39,608 shares — an estimated $192K sold.
Verdad Advisers first reported a position in ZNTL in Q2 2026 and held it in 1 quarter. The position peaked at $192K in Q2 2026. 118 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.
- Verdad Advisers reported no remaining Zentalis Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Verdad Advisers sold 39,608 Zentalis Pharmaceuticals shares in Q3 2026, an estimated $192K.
- Verdad Advisers first reported a position in Zentalis Pharmaceuticals in Q2 2026 and held it in 1 quarter.
- Verdad Advisers's Zentalis Pharmaceuticals position peaked at $192K in Q2 2026.
- 118 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.
Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.